The Evolving Management and Treatment Options for Patients with Pulmonary Hypertension: Current Evidence and Challenges

References

• Simmoneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019;53(1):18001913.
   Web of Science ®Google Scholar
• Humbert M, Guignabert C, Bonnet S, et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J. 2019;53(1):1801887. doi:10.1183/13993003.01887-2018
   PubMed Web of Science ®Google Scholar
• Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022:2200879. doi:10.1183/13993003.00879-2022
   Web of Science ®Google Scholar
• Lüthy E. Proceedings: the epidemic of primary pulmonary hypertension in Europe. Pathol Microbiol. 1975;43(2–O):246–247.
   Google Scholar
• Ishibashi-Ueda H, Ohta-Ogo K. Human pathology. In: Fukumoto Y, editor. Diagnosis and Treatment of Pulmonary Hypertension. Singapore: Springer; 2017. doi:10.1007/978-981-287-840-3_8
   Google Scholar
• Gaine S. Pulmonary hypertension. J Am Med Assoc. 2000;284(24):3160–3168. doi:10.1001/jama.284.24.3160
   Web of Science ®Google Scholar
• Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019;53(1):1801904. doi:10.1183/13993003.01904-2018
   PubMed Web of Science ®Google Scholar
• Humbert M, Nunes H, Sitbon O, et al. Risk factors for pulmonary arterial hypertension. Clin Chest Med. 2001;22(3):459–475. doi:10.1016/S0272-5231(05)70284-7
   PubMed Web of Science ®Google Scholar
• Elliott CG, Farber H, Frost A, et al. Reveal registry: medical history and time to diagnosis of enrolled patients. Chest. 2007;132(4):631A. doi:10.1378/chest.132.4_MeetingAbstracts.631a
   Web of Science ®Google Scholar
• Brown LM, Chen H, Halpern S, et al. Delay in recognition of pulmonary arterial hypertension. Chest. 2011;140(1):19–26. doi:10.1378/chest.10-1166
   Web of Science ®Google Scholar
• Rich JD, Rich S. Clinical diagnosis of pulmonary hypertension. Circulation. 2014;130(20):1825–1830. doi:10.1161/CIRCULATIONAHA.114.006971
   Web of Science ®Google Scholar
• Rich S, Dantzker DR, Ayers SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107:216–223. doi:10.7326/0003-4819-107-2-216
   PubMed Web of Science ®Google Scholar
• Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiog. 2010;23:685–713. doi:10.1016/j.echo.2010.05.010
   PubMed Web of Science ®Google Scholar
• Hellenkamp K, Unsold B, Mushemi-Blake S, et al. Echocardiographic estimation of mean pulmonary artery pressure: a comparison of different approaches to assign the likelihood of pulmonary hypertension. J Am Soc Echocardiog. 2018;31(1):89–98. doi:10.1016/j.echo.2017.09.009
   Web of Science ®Google Scholar
• Topyła-Putowska W, Tomaszewski M, Wysokiński A, et al. Echocardiography in pulmonary arterial hypertension: comprehensive evaluation and technical considerations. J Clin Med. 2021;10(15):3229. doi:10.3390/jcm10153229
   Web of Science ®Google Scholar
• Hassoun PM. Pulmonary arterial hypertension. N Engl J Med. 2021;385:2361–2376. doi:10.1056/NEJMra2000348
   PubMed Web of Science ®Google Scholar
• Swisher JW and Kailash S Advances in management of pulmonary hypertension associated with systemic sclerosis. In: New Insights Into Systemic Sclerosis. (Tomcik M, editor)
   Google Scholar
• Rosenfranz S, Preston IR. Right heart catheterization: best practices and pitfalls in pulmonary hypertension. Eur Respir Rev. 2015;24:642–652.
   Google Scholar
• Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium blockers in idiopathic pulmonary arterial hypertension. Circulation. 2005;111:3105–3111.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Herve P, Barbera JA, et al. An official European respiratory society statement: pulmonary haemodynamics during exercise. Eur Respir J. 2017;50(5):1700578. doi:10.1183/13993003.00578-2017
   PubMed Web of Science ®Google Scholar
• Van de Bovenkamp AA, Wijkstra N, Oosterveer FPT, et al. The value of passive leg raise during right heart catheterization in diagnosing heart failure with preserved ejection fraction. Circ Heart Fail. 2022;15(4):e008935. doi:10.1161/CIRCHEARTFAILURE.121.008935
   Web of Science ®Google Scholar
• Vachiery JL, Teford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J. 2019;53:1801897. doi:10.1183/13993003.01897-2018
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Gomber-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and long-term pulmonary Arterial hypertension disease management (REVEAL). Circulation. 2010;122:164–172. doi:10.1161/CIRCULATIONAHA.109.898122
   PubMed Web of Science ®Google Scholar
• Bouchy A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50:1700889. doi:10.1183/13993003.00889-2017
   Web of Science ®Google Scholar
• Wijeratne DT, Lajkosz K, Brogly SB, et al. Increasing incidence and prevalence of World Health Organization Groups 1 to 4 pulmonary hypertension: a population-based cohort study in Ontario, Canada. Circ Cardiovasc Qual Outcomes. 2018;11(2):e003973. doi:10.1161/CIRCOUTCOMES.117.003973
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306–322. doi:10.1016/S2213-2600(15)00543-3
   PubMed Web of Science ®Google Scholar
• Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173(9):1023–1030. doi:10.1164/rccm.200510-1668OC
   PubMed Web of Science ®Google Scholar
• Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376–387. doi:10.1378/chest.09-1140
   PubMed Web of Science ®Google Scholar
• Leber L, Beaudet A, Muller A. Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ. 2021;11(1):1–12. doi:10.1177/2045894020977300
   Web of Science ®Google Scholar
• Strange G, Playford D, Stewart S, et al. Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart. 2012;98(24):1805–1811. doi:10.1136/heartjnl-2012-301992
   PubMed Web of Science ®Google Scholar
• Escribano-Subias P, Blanco I, Lopez-Meseguer M, et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J. 2012;40(3):596–603. doi:10.1183/09031936.00101211
   PubMed Web of Science ®Google Scholar
• Yang X, Mardekian J, Sanders KN, et al. Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol. 2013;32(10):1519–1531. doi:10.1007/s10067-013-2307-2
   PubMed Web of Science ®Google Scholar
• Gillmeyer KR, Lee -M-M, Link A, et al. Accuracy of algorithms to identify pulmonary arterial hypertension in administrative data: a systematic review. Chest. 2019;155(4):680–688. doi:10.1016/j.chest.2018.11.004
   Web of Science ®Google Scholar
• Graham BB, Zhang L, Tuder RM, et al. Histological and pathological diagnosis of pulmonary hypertension: pathological classification of pulmonary vascular lesions. In: editor, Yuan -JX-J. Textbook of Pulmonary Vascular Disease. Springer Science +Business Media, LLC; 2011. doi:10.1007/978-0-387-87429-6_101
   Google Scholar
• Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation. 2004;109(2):159–165. doi:10.1161/01.CIR.0000102381.57477.50
   PubMed Web of Science ®Google Scholar
• Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol. 2009;54(Suppl 1):S10–S19. doi:10.1016/j.jacc.2009.04.006
   PubMed Web of Science ®Google Scholar
• Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor–II gene. Am J Hum Genet. 2000;67(3):737–744. doi:10.1086/303059
   PubMed Web of Science ®Google Scholar
• Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000;26:81–84. doi:10.1038/79226
   PubMed Web of Science ®Google Scholar
• Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. doi:10.1136/bmj.j5492
   PubMed Web of Science ®Google Scholar
• Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II. J Med Genet. 2000;37:741–745. doi:10.1136/jmg.37.10.741
   PubMed Web of Science ®Google Scholar
• Austin ED, Loyd JE. The genetics of pulmonary arterial hypertension. Circ Res. 2014;115(1):189–202. doi:10.1161/CIRCRESAHA.115.303404
   Web of Science ®Google Scholar
• Nasim MT, Ogo T, Ahmed M, et al. Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat. 2011;32(12):1385–1389. doi:10.1002/humu.21605
   PubMed Web of Science ®Google Scholar
• Shintani M, Yagi H, Nakayama T, et al. A new nonsense mutation of SMAD 8 associated with pulmonary arterial hypertension. J Med Genet. 2009;46:331–337. doi:10.1136/jmg.2008.062703
   PubMed Web of Science ®Google Scholar
• Graf S, Haimel M, Bleda M, et al. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension. Nat Commun. 2018;9(1):1416. doi:10.1038/s41467-018-03672-4
   PubMedGoogle Scholar
• Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Eng J Med. 2001;345(5):325–334. doi:10.1056/NEJM200108023450503
   PubMed Web of Science ®Google Scholar
• Chaouat A, Coulet F, Favre C, et al. Endoglin germline mutation in a patient with hereditary hemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax. 2004;59:446–448. doi:10.1136/thx.2003.11890
   PubMed Web of Science ®Google Scholar
• Ma L, Roman-Campos D, Austin ED, et al. A novel channelopathy in pulmonary arterial hypertension. N Eng J Med. 2013;369(4):351–361. doi:10.1056/NEJMoa1211097
   PubMed Web of Science ®Google Scholar
• Austin ED, Ma L, LeDuc C, et al. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet. 2012;5(3):336–343. doi:10.1161/CIRCGENETICS.111.961888
   PubMedGoogle Scholar
• Best DH, Sumner KL, Austin ED, et al. EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest. 2014;145(2):231–236. doi:10.1378/chest.13-2366
   PubMed Web of Science ®Google Scholar
• Eyries M, Montani D, Girerd B, et al. EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet. 2014;46(1):mm65–mm69. doi:10.1038/ng.2844
   Web of Science ®Google Scholar
• Kim GH, Ryan JJ, Marsboom G, et al. Epigenetic mechanisms of pulmonary hypertension. Pulm Circ. 2011;1(3):347–356. doi:10.4103/2045-8932.87300
   PubMedGoogle Scholar
• Wang Y, Kahaleh B. Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. J Cell Mol Med. 2013;17(10):1291–1299. doi:10.1111/jcmm.12105
   PubMed Web of Science ®Google Scholar
• Zhao L, Chen C-N, Hajji N, et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation. 2012;126(4):455–467. doi:10.1161/CIRCULATIONAHA.112.103176
   PubMed Web of Science ®Google Scholar
• Kim J, Kang Y, Kojima Y, et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension. Nat Med. 2013;19:74–82.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Marcki JC, Richter A, et al. Pathology of pulmonary hypertension. Clin Chest Med. 2007;28(1):23–42. doi:10.1016/j.ccm.2006.11.010
   PubMed Web of Science ®Google Scholar
• Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol. 1991;44:1003–1006. doi:10.1136/jcp.44.12.1003
   PubMed Web of Science ®Google Scholar
• Perros F, Dorfmuller P, Souza R, et al. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension. Eur Respir J. 2007;29(3):462–468. doi:10.1183/09031936.00094706
   PubMed Web of Science ®Google Scholar
• Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;186(9):897–908. doi:10.1164/rccm.201202-0335OC
   PubMed Web of Science ®Google Scholar
• Perros F, Dorfmuller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;185(3):311–321. doi:10.1164/rccm.201105-0927OC
   Web of Science ®Google Scholar
• Van Uden D, Boomars K, Kool M. Dendritic cell subsets and effector function in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Front Immunol. 2019;10:11. doi:10.3389/fimmu.2019.00011
   Web of Science ®Google Scholar
• El Kasmi KC, Pugliese SC, Riddle SR, et al. Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. J Immunol. 2014;193(2):597–609. doi:10.4049/jimmunol.1303048
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Targeting PDGF pathway in pulmonary arterial hypertension. Expert Opin Ther Targets. 2012;16(11):1055–1063. doi:10.1517/14728222.2012.719500
   PubMed Web of Science ®Google Scholar
• Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333(4):214–221. doi:10.1056/NEJM199507273330403
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159(6):1925–1932. doi:10.1164/ajrccm.159.6.9804054
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732–1739. doi:10.1056/NEJM199306173282402
   PubMed Web of Science ®Google Scholar
• McMurtry MS, Archer SL, Altieri DC, et al. Gene therapy targeting surviving selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest. 2005;115:1479–1491. doi:10.1172/JCI23203
   PubMed Web of Science ®Google Scholar
• Tuder RM, Chacon M, Alger LA, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol. 2001;195(3):367–374. doi:10.1002/path.953
   PubMed Web of Science ®Google Scholar
• Christman B, McPherson C, Newman J, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327(2):70–75. doi:10.1056/NEJM199207093270202
   PubMed Web of Science ®Google Scholar
• MacLean MR, Herve P, Eddahibi S, et al. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol. 2000;131(2):161–168. doi:10.1038/sj.bjp.0703570
   PubMed Web of Science ®Google Scholar
• Welsh DJ, Harnett M, MacLean M, et al. Proliferation and signaling in fibroblasts: role of 5-hydroxytryptamine2A receptor and transporter. Am J Respir Crit Care Med. 2004;170(3):252–259. doi:10.1164/rccm.200302-264OC
   PubMed Web of Science ®Google Scholar
• Lee SL, Wang WW, Lanzillo JJ, et al. Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol. 1994;266(1 Pt 1):L46–L52. doi:10.1152/ajplung.1994.266.1.L46
   Google Scholar
• Tamby MD, Chanseaud Y, Humbert M, et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax. 2005;60:765–772. doi:10.1136/thx.2004.029082
   PubMed Web of Science ®Google Scholar
• Dib H, Tamby MC, Bussone G, et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J. 2012;39(6):1405–1414. doi:10.1183/09031936.00181410
   PubMed Web of Science ®Google Scholar
• Ren W, Watts SW, Fanburg BL. Serotonin transporter interacts with the PDGF beta receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2011;300(3):L486–L497. doi:10.1152/ajplung.00237.2010
   Web of Science ®Google Scholar
• Yuan X-J, Wang J, Juhaszova M, et al. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet. 1998;351(9104):726–727. doi:10.1016/S0140-6736(05)78495-6
   PubMed Web of Science ®Google Scholar
• Yuan X-J, Aldinger AM, Juhaszova M, et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation. 1998;98:1400–1406. doi:10.1161/01.CIR.98.14.1400
   PubMed Web of Science ®Google Scholar
• Archer SL, Gomberg-Maitland M, Maitland ML, et al. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-KV1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol. 2008;294(2):H570–H578. doi:10.1152/ajpheart.01324.2007
   PubMed Web of Science ®Google Scholar
• Caruso P, Dunmore BJ, Schlosser K, et al. Identification of miR-124 as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension via PTBP1 and PKM2. Circulation. 2017;136(25):2451–2467. doi:10.1161/CIRCULATIONAHA.117.028034
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang D, Li M, et al. The metabolic and proliferative state of vascular adventitial fibroblasts in pulmonary hypertension is regulated through a miR-124/PTBP1/PKM axis. Circulation. 2017;136(25):2468–2485. doi:10.1161/CIRCULATIONAHA.117.028069
   PubMed Web of Science ®Google Scholar
• Xu W, Koeck T, Lara AR, et al. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci USA. 2007;104(4):1342–1347. doi:10.1073/pnas.0605080104
   PubMed Web of Science ®Google Scholar
• Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med. 2012;185(3):260–266. doi:10.1164/rccm.201108-1536PP
   PubMed Web of Science ®Google Scholar
• Sutendra G, Michelakis ED. The metabolic basis of pulmonary arterial hypertension. Cell Metab. 2014;19(4):558–573. doi:10.1016/j.cmet.2014.01.004
   PubMed Web of Science ®Google Scholar
• Ryan JJ, Archer SL. Emerging concepts in the molecular basis of pulmonary arterial hypertension: part 1: metabolic plasticity and mitochondrial dynamics in the pulmonary circulation and right ventricle in pulmonary arterial hypertension. Circulation. 2015;131(19):1691–1702. doi:10.1161/CIRCULATIONAHA.114.006979
   PubMed Web of Science ®Google Scholar
• Fernandez AI, Yotti R, Gonzalez-Mansilla A, et al. The biological bases of group 2 pulmonary hypertension. Int J Mol Sci. 2019;20(23):5884. doi:10.3390/ijms20235884
   Web of Science ®Google Scholar
• Aris A, Camara ML. Long-term results of mitral valve surgery in patient with severe pulmonary hypertension. Ann Thorac Surg. 1996;61:1583–1584. doi:10.1016/0003-4975(96)00114-2
   Web of Science ®Google Scholar
• Gerges C, Gerges M, Lang MB, et al. Diastolic pulmonary vascular pressure gradient: a predictor of prognosis in “out-of-proportion” pulmonary hypertension. Chest. 2013;143(3):758–766. doi:10.1378/chest.12-1653
   PubMed Web of Science ®Google Scholar
• Cody RJ, Haas GJ, Binkley PF, et al. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85(2):504–509. doi:10.1161/01.CIR.85.2.504
   PubMed Web of Science ®Google Scholar
• Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 Suppl S):25S–32S. doi:10.1016/j.jacc.2004.02.033
   PubMed Web of Science ®Google Scholar
• Dayeh NR, Ledoux J, Dupuis J. Lung capillary stress failure and arteriolar remodelling in pulmonary hypertension associated with left heart disease (Group 2 PH). Prog Cardiovasc Dis. 2016;59:11–21. doi:10.1016/j.pcad.2016.05.002
   Web of Science ®Google Scholar
• Maron BA, Hess E, Maddox TM, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the veterans affairs clinical assessment, reporting, and tracking program. Circulation. 2016;133(13):1240–1248. doi:10.1161/CIRCULATIONAHA.115.020207
   PubMed Web of Science ®Google Scholar
• Singh N, Dormuller P, Shlobin O, et al. Group 3 pulmonary hypertension: from bench to bedside. Circ Res. 2022;130:1404–1422. doi:10.1161/CIRCRESAHA.121.319970
   Web of Science ®Google Scholar
• McGettrick M, Peacock A. Group 3 pulmonary hypertension: challenges and opportunities. Glob Cardiol Sci Pract. 2020;6. doi:10.21542/gcsp.2020.6
   Google Scholar
• Lu A, Zuo C, He Y, et al. EP3 receptor deficiency attenuates pulmonary hypertension through suppression of Rho/TGF-B1 signaling. J Clin Invest. 2015;125:1228–1242. doi:10.1172/JCI77656
   PubMed Web of Science ®Google Scholar
• Gilbane AJ, Derrett-Smith E, Trindar SL, et al. Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-B-dependent mouse model of pulmonary hypertension and in systemic sclerosis. Am J Respir Crit Care Med. 2015;191:665–677. doi:10.1164/rccm.201408-1464OC
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Gomez-Arroyo J. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox. Am J Respir Cell Mol Biol. 2014;51(4):474–484. doi:10.1165/rcmb.2014-0045TR
   Web of Science ®Google Scholar
• Christou H, Yoshida A, Arthur V, et al. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol. 1998;18(6):768–776. doi:10.1165/ajrcmb.18.6.2980
   PubMed Web of Science ®Google Scholar
• Liang S, Yu H, Chen X, et al. PDGF-BB/KLF4/VEGF signaling axis in pulmonary artery endothelial cell angiogenesis. Cell Physiol Biochem. 2017;41:2333–2349.
   PubMedGoogle Scholar
• Eddahibi S, Hanoun N, Lanfumey L, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000;105(11):1555–1562. doi:10.1172/JCI8678
   PubMed Web of Science ®Google Scholar
• Bourque SL, Davidge ST, Adams MA. The interaction between endothelin-1 and nitric oxide in the vasculature: new perspectives. Am J Physiol Regul Integr Comp Physiol. 2011;300(6):R1288–R1295. doi:10.1152/ajpregu.00397.2010
   PubMed Web of Science ®Google Scholar
• Dinh-Xuan AT, Higenbottam TW, Clelland CA, et al. Impairment of endothelium-dependent pulmonary artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991;324:1539–1547. doi:10.1056/NEJM199105303242203
   PubMed Web of Science ®Google Scholar
• Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodeling in smokers and patients with mild COPD. Eur Respir J. 2002;19:632–638. doi:10.1183/09031936.02.00245902
   PubMed Web of Science ®Google Scholar
• Barbera JA, Peinado VI, Santos S, et al. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med. 2001;164:709–713. doi:10.1164/ajrccm.164.4.2101023
   PubMed Web of Science ®Google Scholar
• Wang Z, White A, Wang X, et al. Mitochondrial fission mediated cigarette smoke-induced pulmonary endothelial injury. Am J Respir Cell Mol Biol. 2020;63:637–651. doi:10.1165/rcmb.2020-0008OC
   Web of Science ®Google Scholar
• Wartski M, Collignon MA. Incomplete recovery of lung perfusion after 3 months in patients with acute pulmonary embolism treated with antithrombotic agents. THESEE Study Group. Tinzaparin ou heparin standard: evaluation dans l’Embolie pulmonaire study. J Nucl Med. 2000;41:1043–1048.
   Web of Science ®Google Scholar
• Simonneau G, Torbicki A, Dorfmuller P, et al. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev. 2017;26(143):160112. doi:10.1183/16000617.0112-2016
   PubMed Web of Science ®Google Scholar
• Bonderman D, Wilkens H, Wahounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33:325–331. doi:10.1183/09031936.00087608
   PubMed Web of Science ®Google Scholar
• Zabini D, Heinemann A, Foris V, et al. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J. 2014;44(4):951–962. doi:10.1183/09031936.00145013
   PubMed Web of Science ®Google Scholar
• Quarck R, Wynants M, Verbeken E, et al. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur Respir J. 2015;46(2):431–443. doi:10.1183/09031936.00009914
   PubMed Web of Science ®Google Scholar
• Le Gal G, Delahousse B, Lacut K, et al. Fibrinogen Aa-Thr312Ala and factor XIII-A Val34Leu polymorphisms in idiopathic venous thromboembolism. Thromb Res. 2007;121:333–338. doi:10.1016/j.thromres.2007.05.003
   Web of Science ®Google Scholar
• Morris TA, Marsh JJ, Chiles PG, et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood. 2009;114:1929–1936. doi:10.1182/blood-2009-03-208264
   PubMed Web of Science ®Google Scholar
• Marsh JJ, Chiles PG, Liang NC, et al. Chronic thromboembolic pulmonary hypertension- associated dysfibrinogenemias exhibit disorganized fibrin structure. Thromb Res. 2013;132:729–734. doi:10.1016/j.thromres.2013.09.024
   PubMed Web of Science ®Google Scholar
• Remkova A, Simkova I, Valkovicova T. Platelet abnormalities in chronic thromboembolic pulmonary hypertension. Int J Clin Exp Med. 2015;8:9700–9707.
   Web of Science ®Google Scholar
• Alias S, Redwan B, Panzenbock A, et al. Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol. 2014;34:810–819. doi:10.1161/ATVBAHA.113.302991
   PubMed Web of Science ®Google Scholar
• Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103:685–692. doi:10.1378/chest.103.3.685
   PubMed Web of Science ®Google Scholar
• Dorfmuller P, Gunther S, Ghigna MR, et al. Microvascular disease in chronic thromboembolic pulmonary hypertension: a role for pulmonary veins and systemic vasculature. Eur Respir J. 2014;44:1275–1288. doi:10.1183/09031936.00169113
   PubMed Web of Science ®Google Scholar
• Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013;218:279–313.
   PubMedGoogle Scholar
• Skoro-Sajer N, Mittermayer F, Panzenboeck A, et al. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2007;176:1154–1160. doi:10.1164/rccm.200702-278OC
   PubMed Web of Science ®Google Scholar
• Reesink HJ, Meijer RC, Lutter R, et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ J. 2006;70:1058–1063. doi:10.1253/circj.70.1058
   PubMed Web of Science ®Google Scholar
• Galie N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53:1801889. doi:10.1183/13993003.01889-2018
   PubMed Web of Science ®Google Scholar
• Fauvel C, Raitiere O, Boucly A, et al. Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. J Heart Lung Transplant. 2022;41(12):1761–1772. doi:10.1016/j.healun.2022.09.005
   Web of Science ®Google Scholar
• Farmakis IT, Demerouti E, Karyofyllis P, et al. Echocardiography in pulmonary arterial hypertension: is it time to reconsider its prognostic utility? J Clin Med. 2021;10(13):2868. doi:10.3390/jcm10132826
   Web of Science ®Google Scholar
• Benza RL, Gomberg-Maitland M, Miller DP, et al. The REVEAL registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141:354–362. doi:10.1378/chest.11-0676
   PubMed Web of Science ®Google Scholar
• McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. Eur Respir Rev. 2012;123(123):8–18. doi:10.1183/09059180.00008211
   Google Scholar
• Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323–337. doi:10.1016/j.chest.2019.02.004
   PubMed Web of Science ®Google Scholar
• Benza RL, Kanwar MK, Raina A, et al. Development and validation of an abridged version of the REVEAL 2.0 risk score calculator, REVEAL Lite 2, for use in patients with pulmonary arterial hypertension. Chest. 2021;159(1):337–346. doi:10.1016/j.chest.2020.08.2069
   PubMed Web of Science ®Google Scholar
• Chen C, Watson G, Zhao L. Cyclic guanosine monophosphate signalling pathway in pulmonary arterial hypertension. Vascul Pharmacol. 2013;58(3):211–218. doi:10.1016/j.vph.2012.09.001
   Web of Science ®Google Scholar
• Donaldson S, Ogunti R, Kibreab A, et al. Riociguat in the treatment of chronic thromboembolic pulmonary hypertension: an evidence-based review of its place in therapy. Core Evid. 2020;15:31–40. doi:10.2147/CE.S172791
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148–2157. doi:10.1056/NEJMoa050010
   PubMed Web of Science ®Google Scholar
• Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894–2903. doi:10.1161/CIRCULATIONAHA.108.839274
   PubMed Web of Science ®Google Scholar
• Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med. 2011;183(12):1723–1729. doi:10.1164/rccm.201101-0093OC
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Galie’ N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–340. doi:10.1056/NEJMoa1209655
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369:319–329. doi:10.1056/NEJMoa1209657
   PubMed Web of Science ®Google Scholar
• Galie’ N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res. 2004;61:227–237. doi:10.1016/j.cardiores.2003.11.026
   Web of Science ®Google Scholar
• Channick RN, Simmoneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet. 2001;358(9288):1119–1123. doi:10.1016/S0140-6736(01)06250-X
   PubMed Web of Science ®Google Scholar
• Galie’ N, Badesch BD, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46(3):529–535. doi:10.1016/j.jacc.2005.04.050
   Web of Science ®Google Scholar
• Galie’ N, Olschewski H, Oudiz R, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010–3019. doi:10.1161/CIRCULATIONAHA.107.742510
   Web of Science ®Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809–818. doi:10.1056/NEJMoa1213917
   PubMed Web of Science ®Google Scholar
• Galie’ N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2003;2:123–137.
   Google Scholar
• Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485–491. doi:10.7326/0003-4819-112-7-485
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296–302. doi:10.1056/NEJM199602013340504
   PubMed Web of Science ®Google Scholar
• Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40(4):780–788. doi:10.1016/S0735-1097(02)02012-0
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477–1482. doi:10.1161/01.CIR.0000029100.82385.58
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99(14):1858–1865. doi:10.1161/01.CIR.99.14.1858
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Frantz RP, McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): a study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology. 1999;30(3):641–648. doi:10.1002/hep.510300307
   PubMed Web of Science ®Google Scholar
• Cabrol S, Souza R, Jais X, et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2007;26(4):357–362. doi:10.1016/j.healun.2006.12.014
   PubMed Web of Science ®Google Scholar
• Simmoneau G, Barst RJ, Galie’ N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–804. doi:10.1164/ajrccm.165.6.2106079
   Web of Science ®Google Scholar
• Barst RJ, Galie’ N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006;28:1195–1203. doi:10.1183/09031936.06.00044406
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized, controlled trial. J Am Coll Cardiol. 2010;55(18):1915–1922. doi:10.1016/j.jacc.2010.01.027
   PubMed Web of Science ®Google Scholar
• Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127:624–633. doi:10.1161/CIRCULATIONAHA.112.124388
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simmoneau G, Galie’ N, et al. Inhaled iloprost in severe pulmonary hypertension. N Engl J Med. 2002;347:322–329. doi:10.1056/NEJMoa020204
   PubMed Web of Science ®Google Scholar
• Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart. 1998;80(2):151–155. doi:10.1136/hrt.80.2.151
   PubMed Web of Science ®Google Scholar
• Norel X. Prostanoid receptors in the human vascular wall. Sci World J. 2007;7:1359–1374. doi:10.1100/tsw.2007.184
   Google Scholar
• Humbert M, Lau EM, Montani D, et al. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130(24):2189–2208. doi:10.1161/CIRCULATIONAHA.114.006974
   PubMed Web of Science ®Google Scholar
• Mubarek KK. A review of prostaglandin analogues in the management of patients with pulmonary arterial hypertension. Respir Med. 2010;104:9–21. doi:10.1161/01.CIR.103.1.10
   Web of Science ®Google Scholar
• McLaughlin VV, Channick R, Chin KM, et al. Effect of selexipag on morbidity/mortality in pulmonary arterial hypertension: results of the GRIPHON study. J Am Coll Cardiol. 2015;65(Suppl A):A380. doi:10.1016/S0735-1097(15)61538-8
   Google Scholar
• Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522–2533. doi:10.1056/NEJMoa1503184
   PubMed Web of Science ®Google Scholar
• Gaine S, Chin K, Coghlan G, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50:1602493. doi:10.1183/13993003.02493-2016
   Web of Science ®Google Scholar
• Simmoneau G, Rubin LJ, Nazzareno G, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521–530. doi:10.7326/0003-4819-149-8-200810210-00004
   Web of Science ®Google Scholar
• Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy as an add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30(6):632–643. doi:10.1016/j.healun.2010.11.009
   PubMed Web of Science ®Google Scholar
• Galie’ N, Barbara JA, Frost A, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;379:834–844. doi:10.1056/NEJMoa1413687
   Google Scholar
• D’Alto M, Badagliacca R, Giudice FL, et al. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. J Heart Lung Transplant. 2020;39(12):1389–1397. doi:10.1016/j.healun.2020.08.016
   Web of Science ®Google Scholar
• Chin KM, Sitbon O, Doelberg M, et al. Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol. 2021;78:1393–1403. doi:10.1016/j.jacc.2021.07.057
   PubMed Web of Science ®Google Scholar
• Farmakis IT, Vrana E, Mouratoglou S-A, et al. Haemodynamic effects of initial combination therapy in pulmonary arterial hypertension: a systematic review and meta-analysis. ERJ Open Res. 2022;8(4):00313–2022. doi:10.1183/23120541.00313-2022
   Google Scholar
• Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults. CHEST guideline and expert panel report. Chest. 2014;146(2):449. doi:10.1378/chest.14-0793
   PubMed Web of Science ®Google Scholar
• Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J. 2013;41(2):462–468. doi:10.1183/09031936.00049312
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011;124:1973–1981.
   PubMed Web of Science ®Google Scholar
• Tanabe N. Analysis of Chronic Thromboembolic Pulmonary Hypertension (Intractable Disease Database). Tokyo: Ministry of Health, Wealth and Labor; 2008.
   Google Scholar
• Valerio L, Mavromanoli AC, Barco S, et al. Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study. Eur Heart J. 2022;43:3387–3398.
   Web of Science ®Google Scholar
• Pepke-Zaba J, Hoeper MM, Humbert M. Chronic thromboembolic pulmonary hypertension: advances from bench to patient management. Eur Respir J. 2013;41(1):8–9. doi:10.1183/09031936.00181212
   Web of Science ®Google Scholar
• Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med. 2007;48:680–684. doi:10.2967/jnumed.106.039438
   PubMed Web of Science ®Google Scholar
• He J, Fang W, Lv B, et al. Diagnosis of chronic thromboembolic pulmonary hypertension: comparison of ventilation/perfusion scanning and multidetector computed tomography pulmonary angiography with pulmonary angiography. Nucl Med Commun. 2012;33(5):459–463. doi:10.1097/MNM.0b013e32835085d9
   PubMed Web of Science ®Google Scholar
• Madani MM, Auger WR, Preorius V, et al. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2700 patients. Ann Thorac Surg. 2012;94:97–103. doi:10.1016/j.athoracsur.2012.04.004
   PubMed Web of Science ®Google Scholar
• D’Armini AM, Morsolini M, Mttiucci G, et al. Pulmonary endarterectomy for distal chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2014;148:1005–1011. doi:10.1016/j.jtcvs.2014.06.052
   PubMed Web of Science ®Google Scholar
• Lankeit M, Krieg V, Hobohm L, et al. Pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2018;37(2):250–258. doi:10.1016/j.healun.2017.06.011
   Web of Science ®Google Scholar
• Delcroix M, Lang I, Pepke-Zaba J, et al. Long-term outcome of patient with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. Circulation. 2016;133:859–871. doi:10.1161/CIRCULATIONAHA.115.016522
   PubMed Web of Science ®Google Scholar
• Quadery SR, Swift AJ, Billings CG, et al. The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2018;52:1800589. doi:10.1183/13993003.00589-2018
   PubMed Web of Science ®Google Scholar
• Hsieh WC, Jansa P, Huang WC, et al. Residual pulmonary hypertension after pulmonary endarterectomy: a meta-analysis. J Thorac Cardiovasc Surg. 2018;156(3):1275–1287. doi:10.1016/j.jtcvs.2018.04.110
   Web of Science ®Google Scholar
• Ogo T. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Curr Opin Pulm Med. 2015;21(5):425–431. doi:10.1097/MCP.0000000000000188
   PubMed Web of Science ®Google Scholar
• Fukui S, Ogo T, Goto Y, et al. Exercise intolerance and ventilatory inefficiency improve early after balloon pulmonary angioplasty in patients with inoperable chronic thromboembolic pulmonary hypertension. Int J Cardiol. 2015;180:66–68. doi:10.1016/j.ijcard.2014.11.187
   PubMed Web of Science ®Google Scholar
• Feinstien JA, Goldhaber SZ, Lock JE, et al. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation. 2001;103:10–13.
   Web of Science ®Google Scholar
• Darocha S, Pietura R, Pietrasik A, et al. Improvement in quality of life and hemodynamics in chronic thromboembolic pulmonary hypertension treated with balloon pulmonary angioplasty. Circ J. 2017;81(4):552–557. doi:10.1253/circj.CJ-16-1075
   PubMed Web of Science ®Google Scholar
• Mahmud E, Behnamfar O, Ang L, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Interv Cardiol Clin. 2018;7:103–117. doi:10.1016/j.iccl.2017.09.003
   Google Scholar
• Wiedenroth CB, Liebetrau C, Breithecker A, et al. Combined pulmonary endarterectomy and balloon angioplasty in patients with chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant. 2016;35:591–596. doi:10.1016/j.healun.2015.10.030
   PubMed Web of Science ®Google Scholar
• Simmonneau G, D’Armini AM, Ghofrani H-A, et al. Riociguat for the treatment of thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J. 2015;45(5):1293–1302. doi:10.1183/09031936.00087114
   Web of Science ®Google Scholar
• Ghofrani HA, Simmoneau G, D’Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomized, double-blind, placebo-controlled study. Lancet Respir Med. 2017;5:785–794. doi:10.1016/S2213-2600(17)30305-3
   PubMed Web of Science ®Google Scholar
• Sadushi-Kolici R, Jansa P, Kopec G, et al. Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTEPH): a double-blind, phase 3, randomized controlled trial. Lancet Respir Med. 2019;7:239–248. doi:10.1016/S2213-2600(18)30367-9
   PubMed Web of Science ®Google Scholar
• Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation. 2009;120(13):1248–1254. doi:10.1161/CIRCULATIONAHA.109.865881
   PubMed Web of Science ®Google Scholar
• Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141(3):702–710. doi:10.1016/j.jtcvs.2010.11.024
   PubMed Web of Science ®Google Scholar
• Sueta CA, Gheorghiade M, Adams KF, et al; Epoprostenol Multicenter Research Group. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol. 1995;75:34A–43A.
   Web of Science ®Google Scholar
• Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1997;134(1):44–54. doi:10.1016/S0002-8703(97)70105-4
   PubMed Web of Science ®Google Scholar
• Vachiery JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J. 2018;51:1701886. doi:10.1183/13993003.01886-2017
   Web of Science ®Google Scholar
• Zhuang XD, Long M, Li F, et al. PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol. 2014;172(3):581–587. doi:10.1016/j.ijcard.2014.01.102
   PubMed Web of Science ®Google Scholar
• Guazzi M, Vicenzi M, Arena R, et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation. 2011;124(2):164–174. doi:10.1161/CIRCULATIONAHA.110.983866
   PubMed Web of Science ®Google Scholar
• Hoendermis ES, Liu LCY, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J. 2015;36(38):2565–2573. doi:10.1093/eurheartj/ehv336
   PubMed Web of Science ®Google Scholar
• Redfield MM, Chen HH, Borlaug BA, et al. RELAX trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268–1277. doi:10.1001/jama.2013.2024
   PubMed Web of Science ®Google Scholar
• Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502–511. doi:10.1161/CIRCULATIONAHA.113.001458
   PubMed Web of Science ®Google Scholar
• Hurdman J, Condliffe R, Elliot CA, et al. Pulmonary hypertension in COPD: results from the ASPIRE registry. Eur Respir J. 2013;41(6):1292–1301. doi:10.1183/09031936.00079512
   PubMed Web of Science ®Google Scholar
• Vizza CD, Hoeper MM, Huscher D, et al. Pulmonary hypertension in patients with COPD: results from COMPERA. Chest. 2021;160(2):678–689. doi:10.1016/j.chest.2021.02.012
   PubMed Web of Science ®Google Scholar
• Vitulo P, Stanziola A, Confalonieri M, et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial. J Heart Lung Transplant. 2017;36(2):166–174. doi:10.1016/j.healun.2016.04.010
   PubMed Web of Science ®Google Scholar
• Goudie AR, Lipworth BJ, Hopkinson PJ, et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med. 2014;2(4):293–300. doi:10.1016/S2213-2600(14)70013-X
   PubMed Web of Science ®Google Scholar
• Stolz D, Rasch H, Linka A, et al. A randomized, controlled trial of bosentan in severe COPD. Eur Respir J. 2008;32(3):619–628. doi:10.1183/09031936.00011308
   PubMed Web of Science ®Google Scholar
• Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomized, placebo-controlled phase 2b study. Lancet Respir Med. 2019;7:780–790. doi:10.1016/S2213-2600(19)30250-4
   PubMed Web of Science ®Google Scholar
• Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325–334. doi:10.1056/NEJMoa2008470
   PubMed Web of Science ®Google Scholar
• Bartolome S, Hoeper MM, Klepetko W. Advanced pulmonary arterial hypertension: mechanical support and lung transplantation. Eur Respir Rev. 2017;26(146):170089. doi:10.1183/16000617.0089-2017
   Web of Science ®Google Scholar
• Moser B, Jaksch P, Taghavi S, et al. Lung transplantation for idiopathic pulmonary arterial hypertension on intraoperative and postoperatively prolonged extracorporeal membrane oxygenation provide optimally controlled reperfusion and excellent outcome. Eur J Cardiothorac Surg. 2018;53:178–185. doi:10.1093/ejcts/ezx212
   Web of Science ®Google Scholar
• Kuntz CL, Hadjiliadis D, Ahya VN, et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study. Clin Transplant. 2009;23(6):819–830. doi:10.1111/j.1399-0012.2008.00951.x
   PubMed Web of Science ®Google Scholar
• Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest. 2007;131(4):977–983. doi:10.1378/chest.06-1227
   PubMed Web of Science ®Google Scholar
• Horn EM, Chakinala M, Oudiz R, et al. Could pulmonary arterial hypertension patients be at a lower risk from severe COVID-19? Pulm Circ. 2020;10(2):204589402092279.
   Web of Science ®Google Scholar
• Scuri P, Iacovoni A, Abete R, et al. An unexpected recovery of patients with pulmonary arterial hypertension and SARS-CoV-2 pneumonia: a case series. Pulm Circ. 2020;10(3):204589402095658. doi:10.1177/2045894020956581
   Web of Science ®Google Scholar
• Nuche J, Perez-Olivares C, Segura de la Cal T, et al. Clinical course of COVID-19 in pulmonary arterial hypertension patients. Rev Esp Cardiol. 2020;73(9):775–778. doi:10.1016/j.recesp.2020.05.028
   Web of Science ®Google Scholar
• Farmakis IT, Giannakoulas G. Management of COVID-19 in patients with pulmonary arterial hypertension. Heart Fail Clin. 2023;19:107–114. doi:10.1016/j.hfc.2022.07.003
   Web of Science ®Google Scholar
• Belge C, Quark R, Godinas L, et al. COVID-19 in pulmonary arterial hypertension and chronic Thromboembolic pulmonary hypertension: a reference center survey. ERJ Open Res. 2020;6:00520–2020. doi:10.1183/23120541.00520-2020
   Google Scholar
• Lee JD, Burger CD, Delossantos GB, et al. A survey-based estimate of COVID-19 incidence and outcomes among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension and impact on the process of care. Ann Am Thorac Soc. 2020;17(12):1576–1582. doi:10.1513/AnnalsATS.202005-521OC
   Web of Science ®Google Scholar
• Montani D, Certain M-C, Weatherald J, et al. COVID-19 in patients with pulmonary hypertension: a national prospective cohort study. Am J Respir Crit Care Med. 2022;206(5):573–583. doi:10.1164/rccm.202112-2761OC
   Web of Science ®Google Scholar
• Ackerman M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N Engl J Med. 2020;383:120–128. doi:10.1056/NEJMoa2015432
   Web of Science ®Google Scholar
• Hoffman M, Kleine-Weber H, Krueger N, et al. The novel coronavirus 2019 (2019-nCoV) uses SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. Cell. 2020. doi:10.1016/j.cell.2020.02.052
   Google Scholar
• Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020;220:1–13. doi:10.1016/j.trsl.2020.04.007
   PubMed Web of Science ®Google Scholar
• Profidia A, Pola R. Venous thromboembolism in COVID-19 patients. J Thromb Haemost. 2020;18(6):1516–1517. doi:10.1111/jth.14842
   Web of Science ®Google Scholar
• Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. 2020;41(32):3038–3044. doi:10.1093/eurheartj/ehaa623
   PubMed Web of Science ®Google Scholar
• Torres F, Farber H, Ristic A, et al. Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomized, parallel group, placebo-controlled trial. Eur Respir J. 2019;54:1901030. doi:10.1183/13993003.01030-2019
   PubMed Web of Science ®Google Scholar
• Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384(13):1204–1215. doi:10.1056/NEJMoa2024277
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med. 2010;182(9):1171–1177. doi:10.1164/rccm.201001-0123OC
   PubMed Web of Science ®Google Scholar
• Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J. 1998;11(3):554–559. doi:10.1183/09031936.98.11030554
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128–1138. doi:10.1161/CIRCULATIONAHA.112.000765
   PubMed Web of Science ®Google Scholar
• Frost AE, Barst RJ, Hoeper MM, et al. Long-term safety and efficacy of imatinib in pulmonary arterial hypertension. J Heart Lung Transplant. 2015;34(11):1366–1375. doi:10.1016/j.healun.2015.05.025
   PubMed Web of Science ®Google Scholar
• Kimura G, Kataoka M, Inami T, et al. Sorafenib as a potential strategy for refractory pulmonary arterial hypertension. Pulm Pharmacol Ther. 2017;44:46–49. doi:10.1016/j.pupt.2017.03.009
   Web of Science ®Google Scholar
• Keogh A, Dwyer N, Kotlyar E, et al. Acute hemodynamic improvement in chronic pulmonary arterial hypertension on dual therapy following RT234 inhalation. Chest. 2020;158(4):A2162–A2163. doi:10.1016/j.chest.2020.08.1860
   Web of Science ®Google Scholar
• Lazarus HM, Denning J, Wring S, et al. A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2). Pulm Circ. 2022;12:e12088. doi:10.1002/pul2.12088
   Web of Science ®Google Scholar